[Strategic Combination Approaches in Cancer Immunotherapy].

Recent advances in immune checkpoint inhibitors(ICIs)have transformed cancer therapy, particularly in non‒small cell lung cancer. However, monotherapy achieves limited efficacy due to resistance and an immunosuppressive tumor microenvironment. Rational combination strategies‒chemotherapy, molecular targeted agents, dual checkpoint blockade, antibody‒drug conjugates(ADCs), and radiotherapy‒have shown promise in enhancing antitumor immunity. This review outlines the rationale and clinical evidence behind these combinations, emphasizing current challenges in biomarker development, immune‒related toxicity management, and optimal treatment sequencing for future personalized immunotherapy.